心脏骤停后结局预测的血液生物标志物:TTM2试验内的国际前瞻性观察研究
该研究为TTM2试验内的国际前瞻性观察性生物标志物研究,纳入24家欧洲医院819例院外心脏骤停后昏迷的成年患者,在入ICU后0、24、48、72小时检测血清神经丝轻链蛋白、S100、神经元特异性烯醇化酶和胶质纤维酸性蛋白。主要终点为6个月功能结局(改良Rankin量表0–3为良好,4–6为不良),51%患者结局不良。神经丝轻链蛋白在24、48、72小时的AUROC分别为0.92、0.93、0.93,显著高于第二高的胶质纤维酸性蛋白(P<0.0001),但在0小时无显著差异(P=0.27)。作者结论认为神经丝轻链蛋白是心脏骤停后长期结局的高度准确预测因子,优于本研究中评估的其他相关生物标志物。
要点
- 在心脏骤停后昏迷患者中,神经丝轻链蛋白24小时AUROC为0.92(95%CI 0.90–0.94),48小时为0.93(0.91–0.95),72小时为0.93(0.91–0.95)。
- 神经丝轻链蛋白在24、48、72小时的AUROC显著高于胶质纤维酸性蛋白(P<0.0001),但在0小时无显著差异(P=0.27)。
- 胶质纤维酸性蛋白24小时AUROC为0.87(95%CI 0.84–0.90),神经元特异性烯醇化酶24小时为0.78(0.75–0.82),S100 24小时为0.84(0.81–0.87)。
- 神经元特异性烯醇化酶72小时AUROC为0.86(95%CI 0.82–0.89),S100 72小时为0.78(0.74–0.82)。
- 研究纳入819例患者,51%为不良结局,样本采集时间为入ICU后0、24、48、72小时。
适用人群与场景
- 纳入标准:年龄18岁及以上,院外心脏骤停后昏迷,推测为心脏原因或未知原因,来自24家欧洲医院。
- 排除情况:932例合格患者中113例(12%)因死亡、采样遗漏或结局数据缺失被排除。
诊断标准与关键阈值
- 功能结局评估:6个月改良Rankin量表0–3分为良好结局,4–6分为不良结局。
- 预后准确性评估:采用受试者工作特征曲线下面积(AUROC)。
- 统计学显著性:预设定Bonferroni校正后P<0.0125为显著。
研究设计与关键结果
- 研究类型:国际前瞻性观察性生物标志物研究,嵌套于TTM2试验,来自24家欧洲医院,纳入819例患者,男性661例(81%),女性158例(19%),平均年龄64岁(SD 13),418例(51%)为不良结局。
- 神经丝轻链蛋白预测6个月功能结局的AUROC:0小时0.77(95%CI 0.73–0.80),24小时0.92(0.90–0.94),48小时0.93(0.91–0.95),72小时0.93(0.91–0.95)。
- 胶质纤维酸性蛋白AUROC:0小时0.74(95%CI 0.70–0.77),24小时0.87(0.84–0.90),48小时0.87(0.84–0.90),72小时0.87(0.84–0.91)。
- 神经元特异性烯醇化酶AUROC:0小时0.61(95%CI 0.56–0.65),24小时0.78(0.75–0.82),48小时0.85(0.81–0.88),72小时0.86(0.82–0.89)。
- S100 AUROC:0小时0.74(95%CI 0.71–0.78),24小时0.84(0.81–0.87),48小时0.79(0.75–0.82),72小时0.78(0.74–0.82)。
- 神经丝轻链蛋白在24、48、72小时的AUROC显著高于第二高的胶质纤维酸性蛋白(P<0.0001),0小时无显著差异(P=0.27)。
证据类型、等级与局限
- 证据类型:国际前瞻性观察性生物标志物研究,嵌套于TTM2随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为神经丝轻链蛋白是心脏骤停后长期结局的高度准确预测因子,优于本研究中评估的其他相关生物标志物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Prognostication of recovery in patients who are unconscious following cardiac arrest can be guided by concentrations of brain injury biomarkers in the blood. The optimal biomarker and cutoff concentrations for the prediction of outcome remain unknown. In this study, we aimed to evaluate which biomarker of brain injury is most accurate for predicting functional outcome after cardiac arrest, and to evaluate cutoff levels for the prediction of good and poor outcome.
METHODS: This study was a prospective, international, observational biomarker study within the international Targeted Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial including adults aged 18 years or older with a presumed cardiac cause or unknown cause of arrest. Patients were recruited from 24 European hospitals. Serum samples were collected at 0, 24, 48, and 72 h after admission to intensive care units. Concentrations of neuron-specific enolase, S100, neurofilament light, and glial fibrillary acidic protein were analysed with Elecsys electrochemiluminescence immunoassays. The primary outcome was 6-month good (modified Rankin Scale 0-3) or poor (modified Rankin Scale 4-6) functional outcome. Prognostic accuracy was evaluated by the area under the receiver operating characteristic curve (AUROC). The biomarker with the highest AUROC at each timepoint was compared with that of the second highest marker using DeLong's test. As pre-specified, to account for multiple comparisons using Bonferroni correction, a p value of less than 0·0125 was considered statistically significant.
FINDINGS: Between April, 2018, and January, 2020, 113 (12%) of 932 eligible patients were excluded due to death, missed sampling, or missing outcome data. 661 (81%) of 819 included patients were male and 158 (19%) were female, the mean age was 64 years (SD 13), and 418 (51%) had a poor outcome. In patients who were unconscious, neurofilament light predicted functional outcome with AUROCs at 0, 24, 48, and 72 h of 0·77 (95% CI 0·73-0·80), 0·92 (0·90-0·94), 0·93 (0·91-0·95), and 0·93 (0·91-0·95), respectively. Glial fibrillary acidic protein achieved an AUROC of 0·74 (95% CI 0·70-0·77) at 0 h, 0·87 (0·84-0·90) at 24 h, 0·87 (0·84-0·90) at 48 h, and 0·87 (0·84-0·91) at 72 h. Neuron-specific enolase predicted functional outcome with an AUROC of 0·61 (95% CI 0·56-0·65) at 0 h, 0·78 (0·75-0·82) at 24 h, 0·85 (0·81-0·88) at 48 h, and 0·86 (0·82-0·89) at 72 h. S100 achieved an AUROC of 0·74 (95% CI 0·71-0·78) at 0 h, 0·84 (0·81-0·87) at 24 h, 0·79 (0·75-0·82) at 48 h, and 0·78 (0·74-0·82) at 72 h. Neurofilament light had a statistically significantly higher AUROC than the second highest marker, glial fibrillary acidic protein, at 24, 48, and 72 h (p<0·0001), but not at 0 h (p=0·27).
INTERPRETATION: Neurofilament light is a highly accurate predictor of long-term outcome after cardiac arrest and superior to other relevant biomarkers evaluated in this study.
FUNDING: The Swedish Research Council (Vetenskapsrådet), the Swedish Heart-Lung Foundation, the Stig and Ragna Gorthon Foundation, the Knutsson Foundation, the Laerdal Foundation, the Hans-Gabriel and Alice Trolle-Wachtmeister Foundation for Medical Research, the Bundy Academy at Lund University, Regional Research Support in Skåne, the Swedish Government, and Roche Diagnostics International.
参考来源
- Moseby-Knappe M, Levin H, Ullén S, et al. Blood biomarkers for the prediction of outcome after cardiac arrest: an international prospective observational study within the Targeted Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial. Lancet Respir Med. 2025. PMID: 41391459. doi:10.1016/S2213-2600(25)00363-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。